Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott J Rodig

Showing results (171-180 of 293) with videos related to

Pageof 30
Sort By:
Cancer Cell|December 17, 2013
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphomaBjoern Chapuy, Michael R McKeown, Charles Y Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2019
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II StudyStephen M Ansell, Monique C Minnema, Peter Johnson, et al.
Cancer Immunology Research|October 15, 2016
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 StatusMargaretha G M Roemer, Ranjana H Advani, Robert A Redd, et al.
Journal of Translational Medicine|October 22, 2024
Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinomaMichael J Dennis, Dean C Pavlick, Alec Kacew, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2012
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancerTakeshi Shimamura, Samanthi A Perera, Kevin P Foley, et al.
Nature Communications|July 15, 2023
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLCJoao V Alessi, Biagio Ricciuti, Xinan Wang, et al.
Blood Advances|June 29, 2022
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockadeValentina Tabanelli, Federica Melle, Giovanna Motta, et al.
British Journal of Haematology|September 27, 2014
Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemiaMarc R Mansour, Casie Reed, Amy R Eisenberg, et al.
Nature Medicine|August 12, 2020
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphomaFathima Zumla Cader, Xihao Hu, Walter L Goh, et al.
Cancer Research|October 31, 2012
A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced diseaseDiego J Laderach, Lucas D Gentilini, Laura Giribaldi, et al.
Pageof 30

Showing results (171-180 of 293) with videos related to

Sort By:
Pageof 30
Cancer Cell|December 17, 2013
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphomaBjoern Chapuy, Michael R McKeown, Charles Y Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2019
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II StudyStephen M Ansell, Monique C Minnema, Peter Johnson, et al.
Cancer Immunology Research|October 15, 2016
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 StatusMargaretha G M Roemer, Ranjana H Advani, Robert A Redd, et al.
Journal of Translational Medicine|October 22, 2024
Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinomaMichael J Dennis, Dean C Pavlick, Alec Kacew, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2012
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancerTakeshi Shimamura, Samanthi A Perera, Kevin P Foley, et al.
Nature Communications|July 15, 2023
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLCJoao V Alessi, Biagio Ricciuti, Xinan Wang, et al.
Blood Advances|June 29, 2022
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockadeValentina Tabanelli, Federica Melle, Giovanna Motta, et al.
British Journal of Haematology|September 27, 2014
Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemiaMarc R Mansour, Casie Reed, Amy R Eisenberg, et al.
Nature Medicine|August 12, 2020
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphomaFathima Zumla Cader, Xihao Hu, Walter L Goh, et al.
Cancer Research|October 31, 2012
A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced diseaseDiego J Laderach, Lucas D Gentilini, Laura Giribaldi, et al.
Pageof 30